Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ABEONA THERAPEUTICS INC.v425980_ex99-1.htm



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported): December 1, 2015

 

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware 0-9314 83-0221517
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
     
3333 Lee Parkway, Suite 600, Dallas, TX 75219
(Address of principal executive offices) (Zip Code)

 

(214) 665-9495

(Registrant’s telephone number, including area code)

 

 


(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

  

Item 7.01. Regulation FD Disclosure

Item 8.01. Other Items

 

Presentations relating to our technology, business and corporate financial structure will be made to investors during December 2015. The presentation is attached as Exhibit 99.1 and is incorporated herein.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1Presentation entitled “Abeona Therapeutics”

 

 

 

   

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  Abeona Therapeutics Inc.    
  (Registrant)
     
  By: /s/ Stephen B. Thompson
  Stephen B. Thompson
  Vice President Finance Chief Accounting Officer

  

Date: December 1, 2015

 

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit Number

 

99.1Presentation entitled “Abeona Therapeutics”